Georgy, J. T., Regi, S. S., Georgy, R. V., Sasidharan, B. K., Joel, A., Philip, D. S. J., John, A. O., Thumaty, D. B., Marimuthu, P. K., Jambunathan, P., Harikrishna, K., Thomas, Z., Rani, N. J., Tirkey, A. J., Thomas, M., Isiah, R., Singh, A. (2025). Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Scientific Reports. https://doi.org/10.1038/s41598-025-19197-y